Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

EU Addresses Clinical Trial Integrity Concerns In Face Of COVID-19 Crisis

Risk Assessment Of Pandemic Impact Should Be Done On Blinded Data

Executive Summary

EU guidance offers high-level recommendations on the steps that clinical trial sponsors should take to assess the impact of COVID-19 on the quality and reliability of data being generated in ongoing studies. Early scientific advice is recommended if changes must be made to existing protocols or data analysis plans.

You may also be interested in...



COVID-19: EMA Tackles Trial Data Interpretability

A draft EU guideline explains how companies can ensure that data from ongoing clinical trials remains relevant for regulatory decision-making despite problems posed by the COVID-19 pandemic.

Roche’s Eye Drug Scores First UK Approval Under Access Consortium

The UK MHRA has approved its first drug under an international work-sharing initiative that also includes regulators from Australia, Canada, Singapore and Switzerland.

UK MHRA Specifies Eligibility For Consultancy Firms To Monitor GMP, GDP Compliance

Consultancy firms must have at least five years of experience in carrying out independent GMP or GDP audits if they want to apply to become a “compliance monitor” under a new MHRA scheme to keep track of drug companies that fail to comply with GMP/GDP requirements. 

Topics

UsernamePublicRestriction

Register

PS142467

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel